Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Rep. Pitts To Offer Amendment Excluding Abortion Coverage From House Health Care Bill
Rep. Joe Pitts (R-Pa.) said he plans to introduce an amendment to the House health care overhaul bill (HR 3200) that would prohibit insurers from being required to cover abortion, unless the woman"s life is at risk or the pregnancy is a result of rape or incest, CQ Today reports. Pitts said he will offer the amendment Thursday at the first House Energy and Commerce Committee mark-up session.The House bill would authorize the Obama administration to craft minimum benefit standards for health insurance plans, CQ Today reports. President Obama has said that he considers reproductive health care an essential service. Democrats say Republicans are trying to expand the Hyde amendment"s exclusion on using federal Medicaid funding to cover abortion to all health care services. Rep. Diana DeGette (D-Colo.), vice chair of the Energy and Commerce Committee, said, "I think that if anti-choice Republicans or others see this as an opportunity to expand prohibitions on a legally allowed and medically appropriate practice, then they are wrong." She added, "We are not going to use the health care bill to expand prohibitions on a legal medical practice, period." Pitts, Rep. Christopher Smith (R-N.J.) and other supporters of the amendment say it is necessary to block the administration from requiring abortion coverage. The committee has blocked three of Smith"s abortion-related amendments so far this year (Wayne, CQ Today, 7/15).

FDA Approve One-Pill Version Of Plan B, Sets Over-The-Counter Access At Age 17
FDA approved Teva Pharmaceuticals" Plan B One-Step -- a single-pill version of the two-pill dose emergency contraceptive product Plan B -- and lowered the limit for over-the-counter purchase of the drug to age 17, the company announced on Monday, the AP/Yahoo! Finance reports (AP/Yahoo! Finance, 7/13). Individuals ages 16 and younger will be required to obtain prescriptions to purchase Plan B, which reduces the chance of pregnancy when taken within 72 hours of sexual intercourse (Teva Pharmaceuticals release, 7/13). Teva said the one-pill version will be available at retail pharmacies in August (AP/Yahoo! Finance, 7/13). Kelli Conlin, president of the National Institute for Reproductive Health, said, "Health care providers and women"s advocates have been eager for a one-pill emergency contraceptive for years and are happy to see it finally come to fruition" (Teva Pharmaceuticals release, 7/13).The expanded access to the medication comes several months after a federal court lifted restrictions put in place under former President George W. Bush that limited OTC sales to women ages 18 and older (AP/Yahoo! Finance, 7/13).
News of the day
Inoperable Colon Cancer Responds To New Treatment
With an extensive, inoperable colon cancer and few options available, a Tennessee patient is seeing his cancer steadily regressing on a new outpatient treatment. Individuals from 26 U.S. states and four other countries have been among the first to use NeoPlas Innovation"s new protocol. The Tennessee patient"s early results mirror their successes in battling colon cancer and other very aggressive malignancies.
Diagnostics

Genes Linked To Chemoresistance Identified By Researchers

Two genes may contribute to chemotherapy resistance in drugs like 5-fluorouracil, which is used in liver cancer treatment, according to Virginia Commonwealth University Massey Cancer Center researchers. Liver cancer is a highly aggressive form that has limited therapeutic options. One of the key challenges with cancer treatment is that patients can develop resistance to chemotherapy. Researchers are examining ways to prevent resistance by determining the molecular mechanisms involved with cancer progression, and then developing new generations of chemotherapeutic agents. In the study, published online in the Early Edition of the Proceedings of the National Academy of Sciences the week of July 13, researchers reported that two genes - astrocyte elevated gene-1, or AEG-1, and late SV40 factor, LSF, contribute to resistance of a commonly used chemotherapeutic drug called 5-fluorouracil, or 5-FU. The team found that over-expression of AEG-1 increased resistance of the liver cells to 5-FU. They observed that a second gene, LSF, is under the control of AEG-1 and mediates a series of molecular pathways involved the resistance to 5-FU. Previous studies suggest that the expression of AEG-1, is very low in normal cells or tissues such as breast, prostate, liver and brain. However, in cancers of the same organs, expression of AEG-1 is significantly increased. AEG-1 was initially cloned in the laboratory of Paul B. Fisher, Ph.D., director of the VCU Institute of Molecular Medicine. Earlier this year, the team determined that AEG-1 modulates expression of genes relevant to the progression of liver cancer, including invasion, metastasis, resistance to chemotherapy, the formation of new blood vessels and senescence. They identified that LSF, a transcription factor that regulates gene expression, is increased by AEG-1. "Since AEG-1 is a key regulator of liver cancer development and progression, understanding how this molecule works will provide profound insights into the mechanism of liver cancer development," said principal investigator Devanand Sarkar, Ph.D., a Harrison Endowed Scholar in Cancer Research at the VCU Massey Cancer Center and assistant professor in the Department of Human and Molecular Genetics in the VCU School of Medicine. "By understanding these molecular pathways and mechanisms, we may be able to create new drugs to inhibit the expression of AEG-1 or LSF and even develop combination drug therapies to enhance the effectiveness of 5- fluorouracil." "These findings may have important therapeutic implications. Based on the expression level of AEG-1 or LSF in tumor biopsy samples, a clinician might determine whether a patient would respond to 5-fluorouracil and thus design an effective chemotherapeutic protocol," he said. Sarkar said that AEG-1 contributes to resistance to not only 5-FU, but also to other chemotherapeutics such as doxorubicin and cisplatin, although the molecular mechanism of resistance to the latter drugs is different from 5-FU. The team is currently conducting studies to further understand the molecular mechanisms by which AEG-1 induces resistance to chemotherapy so that this knowledge might be applied to develop strategies to maximize the efficacy of chemotherapeutics. Additionally, novel combinatorial treatment approaches that incorporate AEG-1 or LSF inhibition in a standard chemotherapeutic protocol will be evaluated for their efficacy in inhibiting liver cancer in animal models. This work was supported by grants from The Goldhirsh Foundation, the National Institutes of Health, and the Dana Foundation. Sarkar worked with a team that included VCU School of Medicine researchers Byoung Kwon Yoo, Ph.D., Zao-zhong Su, Ph.D., Rachel Gredler, B.S., Nicollaq Vozhilla, D.V.M., Dong Chen, B.S., and Paul B. Fisher, M.Ph., Ph.D. Also contributing were Talitha Forcier, B.S., and Khalid Shah, Ph.D., from Harvard Medical School; and Utsav Saxena, and Ulla Hansen, Ph.D., from Boston University. The VCU Institute of Molecular Medicine also provided support in conducting these studies. Sathya Achia Abraham Virginia Commonwealth University


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009